## Drug Summary
Amitriptyline, with brand names such as Elavil, Endep, and several others, is a tricyclic antidepressant primarily used to treat major depressive disorder in adults. It exhibits notable efficacy in pain management for conditions such as neuropathic pain, chronic tension-type headache, migraine, and even in children's nocturnal enuresis. Amitriptyline functions by inhibiting the reuptake of norepinephrine and serotonin, thereby increasing their concentration in the synaptic cleft, which helps alleviate depressive symptoms and pain. The drug is absorbed rapidly from the gastrointestinal tract with a variable bioavailability due to first pass metabolism, reaching peak plasma concentrations within 2-12 hours post-administration. Its metabolism is complex, predominantly occurring through CYP2C19, CYP3A4, and CYP2D6 pathways, producing several metabolites including the active form nortriptyline.

## Drug Targets, Enzymes, Transporters, and Carriers
Amitriptyline interacts with multiple targets, including neurotransmitter receptors like the serotonin receptor subtypes (HTR2A, HTR1A, HTR7) and the noradrenaline transporter (SLC6A2). It also impacts various adrenergic, histamine and muscarinic receptors which contribute to its anticholinergic and sedative effects. Enzymatic metabolism of amitriptyline involves several cytochrome P450 enzymes, primarily CYP2D6 and CYP2C19, along with others like CYP1A2 and CYP3A4. These interactions are significant as they affect the drug's plasma levels and efficacy. Amitriptyline is also a substrate for the transporter protein P-glycoprotein (ABCB1) and extensively binds to serum proteins including serum albumin (ALB) and alpha-1-acid glycoprotein 1 (ORM1).

## Pharmacogenetics
The pharmacogenetics of amitriptyline is notable, particularly involving variations in CYP2D6 and CYP2C19 genes, which significantly affect its metabolism. Polymorphisms in these genes can lead to poor or ultrarapid metabolism, influencing both efficacy and the potential for adverse effects. For example, the CYP2D6*10 allele (associated with reduced enzyme activity) can lead to higher plasma levels of amitriptyline, potentially increasing efficacy but also risk of toxicity. Additionally, polymorphisms in the ABCB1 gene (rs2032583) affect the transport of amitriptyline across the blood-brain barrier, thus altering its effectiveness and side effect profile in treating depressive disorders. These genetic variations are critical considerations for personalized medicine approaches in prescribing amitriptyline to ensure optimal dosing and minimize adverse effects.